Showing 2351-2360 of 2656 results for "".
- NIH Selects Dr. Michael Chiang as Director of the National Eye Institutehttps://modernod.com/news/nih-selects-dr-michael-chiang-as-director-of-the-national-eye-institute/2478074/National Institutes of Health Director Francis S. Collins, MD, PhD, has chosen Michael F. Chiang, MD, as director of NIH’s National Eye Institute (NEI). A practicing ophthalmologist, Dr. Chiang is currently the Knowles Professor of Ophthalmology & Medical Informatics and Clinical Epide
- J&J Eyes Late-Stage Study Start of COVID-19 Vaccine in Septemberhttps://modernod.com/news/jj-eyes-late-stage-study-start-of-covid-19-vaccine-in-september/2478037/Johnson & Johnson disclosed alongside its second-quarter earnings call on Thursday that it hopes to begin a late-stage study of its COVID-19 vaccine candidate Ad26.COV2-S in late September, ahead of its previous schedule. The company is in talks with the US National Institutes of Health to br
- Reports Hint at Positive Data Coming for AstraZeneca, Oxford Coronavirus Vaccinehttps://modernod.com/news/reports-hint-at-positive-data-coming-for-astrazeneca-oxford-coronavirus-vaccine/2478028/Reports emerged that positive news will be released soon on AstraZeneca’s experimental COVID-19 vaccine that it is working on with the University of Oxford. The Lancet has also confirmed that data from a phase 1 trial of AZD1222, formerly known as ChAdOx1 nCoV-19, will be published
- AstraZeneca, IQVIA Partner to Speed Up Studies of COVID-19 Vaccine Candidatehttps://modernod.com/news/astrazeneca-iqvia-partner-to-speed-up-studies-of-covid-19-vaccine-candidate/2478022/AstraZeneca and IQVIA are teaming up to accelerate development of the UK drugmaker’s Oxford University-partnered COVID-19 vaccine candidate AZD1222, IQVIA announced Tuesday. According to the life sciences data analytics firm, the collaboration will “drive faster delivery of clin
- Nicox Partner Ocumension Completes Successful Hong Kong IPOhttps://modernod.com/news/nicox-partner-ocumension-completes-successful-hong-kong-ipo/2477998/Nicox SA’s partner Ocumension Therapeutics had a successful IPO on the Hong Kong Stock Exchange and provided an update on the programs in the collaboration. Ocumension Therapeutics began trading on the Hong Kong Stock Exchange on July 10, 2020 after an IPO raising HK $1,424 (~US $184
- Novavax Gains $1.6 Billion in Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-gains-1-6-billion-in-funding-for-covid-19-vaccine-candidate/2477984/Novavax announced that it has been awarded $1.6 billion by the US government to progress development of NVX CoV2373 and potentially deliver 100 million doses of the COVID-19 vaccine as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using Novavax’s nanop
- Haag-Streit Introduces Eyestar 900 OCT Analyzerhttps://modernod.com/news/haag-streit-introduces-eyestar-900-oct-analyser/2477968/Haag-Streit has launched the Eyestar 900, a new swept-source-based precision OCT analyzer. The Eyestar 900, which recently received CE registration, is being launched in various countries and will be widely available in October 2020. The Eyestar 900’s technology enables precise measurement
- After Sale of Ellex Medical Lasers, Nova Eye Medical is Formedhttps://modernod.com/news/nova-eye-medical-launches-to-propel-glaucoma-innovation/2477952/Ellex Medical Lasers has completed the sale of its Ellex Lasers & Ultrasound business to Quantel Medical via Lumibird Group SA, and changed its name from Ellex Medical Lasers Limited to Nova Eye Medical Limited. In December 2019, Lumibird Group, the parent company of Quantel Medical, s
- Samsung Bioepis Initiates Phase 3 Clinical Trial for SB15, Proposed Biosimilar to Eylea (Aflibercept)https://modernod.com/news/samsung-bioepis-initiates-phase-3-clinical-trial-for-sb15-proposed-biosimilar-to-eylea-aflibercept/2477950/Samsung Bioepis announced the initiation of phase 3 clinical trial for SB15, the company’s proposed biosimilar referencing Eylea (aflibercept). The trial is a randomized, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity b
- NIH Becomes Latest to Halt COVID-19 Trial of Hydroxychloroquinehttps://modernod.com/news/nih-becomes-latest-to-halt-covid-19-trial-of-hydroxychloroquine/2477917/Another clinical trial testing hydroxychloroquine in hospitalized patients with COVID-19 has been stopped, this one by the US National Institutes of Health (NIH). The agency said that the ORCHID study’s data and safety monitoring board found, after having conducted its fourth interim analys